IVVD
Get informed when a big investor buys or sells
+ FollowUndervalued by 291.4% based on the discounted cash flow analysis.
| Market cap | $151.31 Million |
|---|---|
| Enterprise Value | $-24,215,436.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.3 |
| Beta | 0.71 |
| Outstanding Shares | 309,670,101 |
| P/E Ratio | -4.55 |
|---|---|
| PEG | -2.95 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -0.43 |
| Enterprise Value to EBIT | 0.29 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.36 |
| Debt to Equity | 0.04 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3663▼ 22.50% |
|---|---|
| Total Calls | 561,000▼ 19.97% |
| Total Puts | 205,500▼ 50.42% |
Holdings and activity of institutional investors.
| Ownership % | 131.50%▼ 9.63% |
|---|---|
| Total Invested | $294.24M▼ 50.44% |
| Investors Holding | 146▲ 25.00% |
No data
Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antib...